Recurrent Gynecologic Cancer Treatment

Drug Source Year Author # Patients Result
Chemotherapy
Paclitaxel GOG 2013 Van-Le Muggia Ahead of Pub Ahead of Pub
BEP (bleomycin, etoposide, cisplatin) GOG 2008 Pautier 20 PR=45%; CR=45%*
BEP (bleomycin, etoposide, cisplatin) GOG 1999 Homesley 14 CR=37%
CAP (cyclophosphamide, doxorubicin, cisplatin) Case Series 1992 Pectasides 10 RR=60%
Hormone
Leuprolide Case Series 1996 Fishman 2 RR=40%
Megestrol + Tamoxifen Case Series 2005 Hardy 1 RR=100%
Biologics
Bevasizumab GOG 2014 Brown 36 RR=16.7%; Stable disease = 77.8%
Bevasizumab Case Series 2009 Tao 8 RR=38%
Radiation
XRT Case Series 1999 Wolf 6 RR=43%
*PR = partial response; CR = complete response; RR = response rate
Drug Source Year Author # Patients Result
Chemotherapy
Paclitaxel+Carboplatin GOG 2010 Powell Ahead of Pub Ahead of Pub
BEP (bleomycin, etoposide, cisplatin) GOG 2008 Pautier 55 RR=54%
BEP (bleomycin, etoposide, cisplatin) GOG 1999 Homesley 14 CR=37%
Ifosfamide Case Series 1996 Sutton 52 RR=15%
Topotecan Case Series 2003 Walder 44 RR=20%
Biologic
Bevasizumab Case Series 2011 Aghajanian 53 RR=15%; PFS* at 6 mo. = 36%
*PFS = progression free survival
Drug Source Year Author # Patients Result
Chemotherapy, prior
Albumin-bound paclitaxel GOG 2011 Alberts 35 RR = 29%
Gemcitabine-CDDP GOG 2002 Brewer 32 RR = 22%
Pemetrexed GOG 2006 Miller 27 RR = 15%
Vinorelbine GOG 1999 Muggia 44 RR = 14%
Topotecan GOG 1996 Bookman 40 RR = 13%
Liposomal Dox GOG 2003 Rose 27 RR = 11%
Ifosfamide GOG 1996 Sutton 51 RR = 31.1%
Biologic
Bevacizumab GOG 2006 Monk 46 RR = 11%; 6 mon PFS = 24%
Cetuximab GOG 2009 Santin 35 RR = 0%; 6 mon PFS = 14%
Chemotherapy, no
Paclitaxel GOG 1993 McGuire 52 RR = 17%
Topotecan GOG 1995 Muderspach 43 RR = 18.6%
Cisplatin + Paclitaxel GOG 1997 Rose 41 RR = 46.3%
Cisplatin + Vinorelbine GOG 2001 Morris 67 RR = 29.9%
Capecitabine GOG 2003 Garcia 26 RR = 15.4%
Cisplatin + Pemetrexed GOG 2011 Miller 54 RR = 31%
Radiation
XRT Case Series 2008 Haasbeek 35 DFS = 40-50%
Drug Source Year Author # Patients Result
Chemotherapy, prior
Paclitaxel GOG 2001 Curtin 42 RR = 31%
Vinorelbine GOG 2005 Muggia 28 RR = 7%
Gemcitabine GOG 2005 Schilder 22 RR = 4.5%; PFS = 36.4%
Ifosfamide GOG 1993 Sutton 41 RR = 15%
Capecitabine GOG 2008 Look 21 PFS = 45%
Hormone
Tamoxifen GOG 2004 Bigler 34 RR = 11%
Drug Source Year Author # Patients Result
Paclitaxel GOG 1996 Lincoln 44 RR = 27.3%; no prior taxane allowed
Paclitaxel GOG 1996 Ball 30 RR = 36%; no prior therapy
Topotecan Case Series 2003 Wadler 44 RR = 20%
Ifosfamide GOG 1996 Sutton 37 RR = 24.3%; no prior therapy
Hormone
Tamoxifen GOG 2001 Thigpen 68 RR = 10%
Tamoxifen + Progesterone GOG 2009 Whitney 61 RR = 33%
Biologic
Bevacizumab GOG 2008 Aghajanian 52 RR = 13.5%; PR>6 mo 40.4%
VEGF-Trap (Aflibercept) GOG 2009 Coleman 44 RR = 6.8%; PR>6 mo 40.9%
Bevacizumab + Temsirolimus GOG 2010 Alvarez 49 RR = 24.5%; PR> 6 mo 46.9%
Brivanib GOG 2014 Powell 45 RR = 18.6%; PFS> 6 mon 30.2%
Temsirolimus GOG 2011 Oza 33 RR = 14%; stable disease = 69%
Drug Source Year Author # Patients Result
Chemotherapy
Docetaxel GOG 2000 Rose 58 RR = 22%
Paclitaxel (weekly) GOG 2002 Markman 48 RR = 25%
Pemetrexed GOG 2009 Miller 48 RR = 21%
Nab-Paclitaxel GOG 2011 Coleman 47 RR = 23%
Pegylated liposomal doxorubicin Case Series 2001 Gordon 239 RR = 20%
Topotecan (daily x 5 days) Case Series 2011 Sehouli 194 RR = 58%
Etoposide GOG 1998 Rose 41 RR = 26.8%
Biologic
Bevacizumab GOG 2007 Burger 62 RR = 21%
Hormone
Tamoxifen Review 2001 Williams 623 RR = 10%
Drug Source Year Author # Patients Result
Chemotherapy
Topotecan GOG 1996 McGuire 46 RR = 33%
Pyrazoloacridine GOG 1998 Plaxe 42 RR = 23.8%
Topotecan (daily vs. weekly) GOG 2008 Herzog 15 (daily); 65 (weekly) RR = 27% (daily); 12% (weekly)
Tirapazamine + Cisplatin GOG 2004 Covens 64 RR = 53%
Cetuximab + Carboplatin GOG 2005 Secord 26 RR = 34.6%
Carboplatin + Gemcitabine Case Series 2006 Pfisterer 178 PFS = 8.6 mon (vs. 5.8 mon only Carbo)
Etoposide GOG 1998 Rose 41 RR = 34%
Pegylated liposomal doxorubicin Case Series 2000 Gordon 82 RR = 18.3%
Gemcitabine Case Series 2008 Ferrandina 153 RR = 29%
Nanoparticle albumin bound (nAb) paclitaxel GOG 2011 Coleman 47 RR = 23%; PFS> 6 mo = 36%
Biologic
Bevacizumab GOG 2004 Burger 62 RR = 21%; PFS >6 mo = 40.3%
Sorafenib (BAY 43-9006) GOG 2007 Matei 59 RR = 3.4%; PFS >6 mon = 23.7%
Temsirolimus (CCI779) GOG 2011 Behbakht 54 RR = 9.3%; PFS >6 mon = 24.1%
Dasatinib (BMS354825) GOG 2009 Schilder 34 RR = 0%; PFS >6 mon = 20.6%
Drug Source Year Author # Patients Result
Chemotherapy
PG-paclitaxel (235 mg) GOG 2003 Sabbatini 25 RR = 20%
Trabectedin (ET-743)-Docetaxel GOG 2009 Monk 71 RR = 30%
Drug Source Year Author # Patients Result
PARP Inhibitor
Veliparib GOG 2015 Coleman 50 RR = 20% (plat resistant); 35% (plat sensitive)